Staphylokinase which is extracted from Staphylococci has been known for more than 40 years as a profibrinolytic compound. It has been obtained more recently by genetic engineering. Staphylokinase activates plasminogen into plasmin. It is a promising new thrombolytic agent for the treatment of acute myocardial infarction and thromboembolic disease in general. It is a fibrin specific thrombolytic agent which does not decrease plasma fibrinogen level in treated patients. However it is antigenic and the group of Louvain has made much effort to reduce its antigenicity without decreasing its thrombolytic activity. Mutants with a reduced antigenic activity have been recently obtained. These new thrombolytic agents could be superior to currently used drugs. Staphylokinase mutants could have a better benefit/cost ratio than other thrombolytic agents.
Download full-text PDF |
Source |
---|
Lancet Neurol
February 2025
Department of Medicine, McMaster University, Population Health Research Institute, Hamilton, ON, Canada.
Background: People with subclinical atrial fibrillation are at increased risk of stroke, albeit to a lesser extent than those with clinical atrial fibrillation, leading to an ongoing debate regarding the benefit of anticoagulation in these individuals. In the ARTESiA trial, the direct-acting oral anticoagulant apixaban reduced stroke or systemic embolism compared with aspirin in people with subclinical atrial fibrillation, but the risk of major bleeding was increased with apixaban. In a prespecified subgroup analysis of ARTESiA, we tested the hypothesis that people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack, who are known to have an increased risk of recurrent stroke, would show a greater benefit from oral anticoagulation for secondary stroke prevention compared with those without a history of stroke or transient ischaemic attack.
View Article and Find Full Text PDFBr J Hosp Med (Lond)
January 2025
Department of Osteoarthritis, Yantai City Yantai Shan Hospital, Yantai, Shandong, China.
Deep venous thrombosis (DVT) represents a significant postoperative complication after artificial femoral head replacement, with the incidence increasing proportionally with patient age. This study aimed to evaluate the effect of early postoperative use of intermittent pneumatic compression devices (IPC), followed by the combined use of low molecular weight heparin (LMWH) after 48 hours, for the prevention of postoperative lower limb DVT in elderly patients undergoing hip arthroplasty. The retrospective study included 100 elderly patients who underwent unilateral femoral head replacement.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Division of Hand Surgery, Plastic Surgery and Aesthetic Surgery, University Hospital, LMU Munich, Ziemssenstraße 5, 80336 Munich, Germany.
Aspirin (ASA) is one of the most used medications worldwide and has shown various effects on cellular processes, including stem cell differentiation. However, the effect of ASA on adipogenesis of adipose tissue-derived stem cells (ASCs) remains largely unknown. Considering the potential application of ASCs in regenerative medicine and cell-based therapies, this study investigates the effects of ASA on adipogenic differentiation in human ASCs.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
General Dentistry, Department of Oral Health Science, Faculty of Dental Medicine, Hokkaido University, N13W7, Kita-ku, Sapporo 060-8586, Japan.
Lactoferrin is a highly safe antibacterial protein found in the human body and in foods. Calcium phosphate (CaP) nanoparticles with immobilized lactoferrin could therefore be useful as intraoral disinfectants for the prevention and treatment of dental infections because CaP is a mineral component of human teeth. In this study, we fabricated CaP nanoparticles with co-immobilized lactoferrin and heparin using a simple one-step coprecipitation process.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Department of Biology, Faculty of Science, University of Zagreb, Horvatovac 102, 10000 Zagreb, Croatia.
The role of the plasminogen activation system is to regulate the activity of the extracellular protease plasmin. It comprises the urokinase plasminogen activator (uPA), a specific extracellular protease which activates plasminogen, its inhibitor PAI1, and the urokinase plasminogen activator receptor, uPAR, which localizes the urokinase activity. The plasminogen activation system is involved in tissue remodeling through extracellular matrix degradation, and therefore participates in numerous physiological and pathological processes, which make it a potential biomarker.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!